Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Chemotherapy in Metastatic Urothelial Cancer
DRKS00008947Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 29
01
Overview
Phase 3, randomised trial of pembrolizumab in transitional cell carcinoma (TCC), bladder cancer and ureteral cancer (2 arms), sponsored by Merck & Co. Started Aug 2015; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancerureteral cancer
Beyond the preview
Go deeper on DRKS00008947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00008947.